ONCOZ — Oncozenge AB Share Price
Last trade - 00:00- SEK35.37m
- SEK25.71m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.35 | ||
| Price to Tang. Book | 4.07 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -87.43% | ||
| Return on Equity | -61.58% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | 40 | 2 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OncoZenge AB is a Sweden-based pharmaceutical company, that develops products for cancer supportive care. OncoZenge's vision is to improve the quality of life for patients with severe oral pain, for example caused by radiotherapy or chemotherapy in the treatment of cancer. The Company works on the introduction of its project BupiZenge. Its strategic and operational work focuses on the development of BupiZenge, which is a formulation of bupivacaine in the form of a lozenge. BupiZenge meets a need for pain relief in the mouth and throat, for example associated with oral mucositis, a serious complication after radiation or other cancer treatment. Preparations for registration establishment clinical studies are ongoing.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- July 2nd, 2020
- Public Since
- February 12th, 2021
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 11,713,244
- Address
- Gustavslundsvagen 34, BROMMA, 167 51
- Web
- https://oncozenge.se/
- Phone
- +46 8311420
- Auditors
- Grant Thornton
Upcoming Events for ONCOZ
Similar to ONCOZ
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Calliditas Therapeutics AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cinclus Pharma Holding publ AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 22:29 UTC, shares in Oncozenge AB are trading at SEK3.27. This share price information is delayed by 15 minutes.
Shares in Oncozenge AB last closed at SEK3.27 and the price had moved by -44.58% over the past 365 days. In terms of relative price strength the Oncozenge AB share price has underperformed the FTSE Global All Cap Index by -51.26% over the past year.
There is no consensus recommendation for this security.
Oncozenge AB does not currently pay a dividend.
Oncozenge AB does not currently pay a dividend.
Oncozenge AB does not currently pay a dividend.
To buy shares in Oncozenge AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK3.27, shares in Oncozenge AB had a market capitalisation of SEK38.30m.
Here are the trading details for Oncozenge AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: ONCOZ
Based on an overall assessment of its quality, value and momentum Oncozenge AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Oncozenge AB is SEK2.50. That is 23.55% below the last closing price of SEK3.27.
Analysts covering Oncozenge AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK0.68 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncozenge AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -2.62%.
As of the last closing price of SEK3.27, shares in Oncozenge AB were trading -5.47% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Oncozenge AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK3.27.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Oncozenge AB's directors